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Abstract
Background: Gastric contents aspiration in humans is a risk factor for severe respiratory failure with elevated mortality.
Although aspiration-induced local lung inflammation has been studied in animal models, little is known about
extrapulmonary effects of aspiration. We investigated whether a single orotracheal instillation of whole gastric
fluid elicits a liver acute phase response and if this response contributes to enrich the alveolar spaces with proteins
having antiprotease activity.
Methods: In anesthetized Sprague-Dawley rats receiving whole gastric fluid, we studied at different times after
instillation (4 h −7 days): changes in blood cytokines and acute phase proteins (fibrinogen and the antiproteases
alpha1-antitrypsin and alpha2-macroglobulin) as well as liver mRNA expression of the two antiproteases. The impact of
the systemic changes on lung antiprotease defense was evaluated by measuring levels and bioactivity of antiproteases
in broncho-alveolar lavage fluid (BALF). Markers of alveolar-capillary barrier derangement were also studied.
Non-parametric ANOVA (Kruskall-Wallis) and linear regression analysis were used.
Results: Severe peribronchiolar injury involving edema, intra-alveolar proteinaceous debris, hemorrhage and PMNn cell
infiltration was seen in the first 24 h and later resolved. Despite a large increase in several lung cytokines, only IL-6 was
found elevated in blood, preceding increased liver expression and blood concentration of both antiproteases. These
changes, with an acute phase response profile, were significantly larger for alpha2-macroglobulin (40-fold increment in
expression with 12-fold elevation in blood protein concentration) than for alpha1-antitrypsin (2–3 fold increment in
expression with 0.5-fold elevation in blood protein concentration). Both the increment in capillary-alveolar antiprotease
concentration gradient due to increased antiprotease liver synthesis and a timely-associated derangement of the
alveolar-capillary barrier induced by aspiration, contributed a 58-fold and a 190-fold increase in BALF alpha1-antitrypsin
and alpha2-macroglobulin levels respectively (p < 0.001).
(Continued on next page)
* Correspondence: gborzone@med.puc.cl
1Department of Respiratory Diseases and Medical Research Center, Faculty of
Medicine, Pontificia Universidad Católica de Chile, Marcoleta 350, piso 1,
Santiago, Chile
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ayala et al. Respiratory Research  (2016) 17:71 
DOI 10.1186/s12931-016-0379-7
(Continued from previous page)
Conclusions: Gastric contents-induced acute lung injury elicits a liver acute phase response characterized by increased
mRNA expression of antiproteases and elevation of blood antiprotease concentrations. Hepatic changes act in concert
with derangement of the alveolar capillary barrier to enrich alveolar spaces with antiproteases. These findings may
have significant implications decreasing protease burden, limiting injury in this and other models of acute lung injury
and likely, in recurrent aspiration.
Keywords: Aspiration, Liver acute phase response, Acute phase proteins, α1-antitrypsin, α2-macroglobulin,
Alveolar-capillary barrier, Lung antiprotease defense
Background
Gastric contents aspiration is defined as the inhalation
of gastric material into the airways below the level of the
vocal cords, with consequences that are variable, ranging
from an almost asymptomatic episode to severe acute
lung injury (ALI) with high mortality [1, 2]. In fact, gas-
tric contents aspiration is a major direct cause of ALI.
Although the true incidence of aspiration-induced lung
injury is difficult to estimate considering that many as-
piration events are silent, trauma and ICU patients with
altered states of consciousness as well as patients requir-
ing emergency anesthesia are at high risk of aspiration
[2]. The deleterious effects of aspiration also depend on
the terrain in which it occurs, as recently shown by Tsai
et al., who found that aspiration of gastro-esophageal re-
flux increases the risk of intensive care unit admission
and mechanical ventilation use among patients with
chronic obstructive pulmonary disease [3].
The initial local lung effects of aspiration have been
extensively studied in animal models [2, 4–15]. These
effects include severe derangement of the alveolar ca-
pillary barrier with extravasation of plasma constituents
from the vascular to the alveolar spaces, polymorpho-
nuclear neutrophil recruitment and expression of pro-
inflammatory mediators. Recently, we contributed to
the understanding of resolution of the initial ALI in-
duced by whole gastric juice in a rat model [5], showing
that resolution involves an organizing pneumonia with
granuloma formation, that later resolves.
However, very little is known about effects outside of
the lung that are likely to occur in association with local
lung effects and that may have important implications in
the course of ALI and its prognosis.
Stimulated by a complex intercellular signaling sys-
tem involving pro-inflammatory cytokines, the liver
responds to inflammation localized in distant organs,
with the acute phase response (APR) [16], a response
that has been studied in rodents with a variety of
stimuli such as LPS, turpentine administration and
exposition to thermal injury [17, 18], all stimuli that
do not affect the lung primarily. This response is
characterized by significant changes in blood levels
of acute phase proteins (APPs), such as C-reactive
protein, clotting and complement proteins and pro-
teinase inhibitors [16].
Very limited studies have investigated the APR in rela-
tion to inflammatory processes affecting the lung pri-
marily [19, 20] but interestingly, these studies have not
evaluated whether or not liver-synthesized lung antipro-
teases are involved.
We hypothesized that aspiration-induced lung inflam-
mation elicits a hepatic APR. We also hypothesized that
increased blood levels of antiproteases will be part of
this response and will contribute to increase bronchoal-
veolar lavage fluid (BALF) levels of antiproteases.
The aim of our work was to investigate whether and
to what extent aspiration of gastric fluid induces a hep-
atic acute phase response in a rat model of orotracheal
instillation of whole gastric fluid, and if so, to determine
the effects of this response on lung antiprotease levels.
This model has been well characterized by our group ac-
cording to ATS recommendations [21], and meets all
the requirements for a model of ALI with severe histo-
logical and physiological changes, which resolve leaving
normal lung architecture [5].
We found that the severe lung inflammatory reaction
induced by orotracheal instillation of whole gastric fluid
elicits significant systemic effects that result in up-
regulation of important lung antiproteases, contributing
to improve lung antiprotease defences, underscoring an
important role of the liver promoting lung tissue pro-
tection in acute lung injury. We believe that under-
standing how the liver response integrates with the
local lung inflammatory response to promote immunity
and tissue protection during aspiration of gastric con-
tents will help to identify new approaches to treat this
condition.
Methods
Animal model of orotracheal instillation of rat whole
gastric fluid
The study was performed according to a protocol
submitted to and approved by the Animal Research
Ethics Committee of the Pontificia Universidad Cató-
lica de Chile.
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Gastric fluid pool
Gastric fluid was obtained through a gastrotomy from
adult male Sprague-Dawley rats (300 ± 10 g) fasted over-
night and anesthetized intra-peritoneally with xylazine-
ketamine (5.1 and 55.1 mg x kg−1, respectively). Gastric
fluid samples were pooled, filtered through a 100 μmmesh
filter and kept at −80 °C. Animals were euthanized there-
after by exsanguination under anesthesia.
Orotracheal instillation
Under the same anesthetic protocol, another set of ani-
mals was orotracheally intubated with a 22G wire-fed
catheter. Visualization of the glottis was achieved using
a modified human otoscope (Welch Allyn®). A volume of
gastric fluid (1.5 ml x kg−1, pH = 1.69) previously found
by us to distribute evenly (data not shown) was instilled
and animals allowed to recover spontaneously from
anesthesia.
Study groups
Animals were studied at 4, 12, 24 h, and at days 4 and 7
after instillation (n = 10 per group). Animals without
intervention served as controls (n = 10).
Sample collection
Blood samples from the vena cava and snap frozen liver
samples were obtained through a laparotomy prior to
opening the thorax. Lungs were excised en bloc and the
left main bronchus cannulated for bronchoalveolar lav-
age. For each animal, three aliquots of 0.15 M saline
(1 ml each) were instilled, immediately aspirated, pooled
and stored at −80 °C. BALF percent recovery was 67 ±
7 %. The right middle lobe was excised to prepare 10 %
tissue homogenates in phosphate buffer. The caudate
lobe was used to obtain the wet-to-dry weight ratio. The
right lower lobe was fixed at 20 cm H2O with 10 % buff-
ered formaldehyde solution and paraffin-embedded for
histologic studies. The right upper lobe was excised and
frozen for biochemical and molecular analysis.
Histologic evaluation
For each animal, four whole lobe longitudinal sections
(5 μm) were obtained and stained with hematoxylin-
eosin for analysis by light microscopy as in [5], following
ATS recommendations [21].
Markers of alveolar-capillary barrier derangement
a) Total protein concentration in BALF was measured
using the Bradford protein assay [22].
b) Lung wet-to-dry weight ratio: The caudate lobe was
removed and weighed immediately. After desiccation at
60 °C the lobe was weighed again to determine its
wet-to-dry weight ratio.
c) In a new set of animals (n = 5 per group), the Evans
blue dye was utilized as a marker for derangement of
the alveolar-capillary barrier [23]. Four hours prior to
sacrifice, the Evans blue dye was injected via tail vein
and its extravasation into BALF was quantified by
spectrophotometry (Shimadzu, Japan).
Levels of pro-inflammatory cytokines and IL-10
Serum, BALF and lung tissue homogenate levels of IL-6,
IL-1β, TNF-α and IL-10 were measured in duplicate
with commercially available enzyme-linked immuno-
sorbent (ELISA) assay kits (Quantikine, R&D Systems,
USA) according to the manufacturer’s instructions. Mi-
croplates were read using a microplate reader (BIO-
TEK® Instruments, INC. Winooski, Vermont, USA).
Levels of blood and BALF acute phase proteins
Changes in the level of three acute phase proteins were
studied in plasma: fibrinogen, α1-AT and α2-MG, whereas
changes in α1-AT and α2-MG were studied in BALF.
a) Fibrinogen: Plasma fibrinogen levels were determined
by the Von Clauss coagulation micro-method [24].
b) α1-AT: Both abundance and bioactivity of this
antiprotease were measured in plasma and BALF:
– Western blot analysis of α1-AT: 30 μg of plasma or
BALF proteins were separated by 10 % SDS-PAGE
and immobilized onto NO2-cellulose membranes
(0.45 μm pore; Thermo Scientific, Rockford, IL,
USA). Membranes were probed with an anti-human
α1-AT rabbit antibody (Sigma, Mississauga, ON,
Canada) and then with a goat anti-rabbit peroxidase-
conjugated antibody (Thermo Scientific, Rockford, IL,
USA). α1-AT immunoreactivity was visualized by
enhanced chemiluminescence (SuperSignal® Pico
Chemiluminescent Substrate kit; Thermo Scientific,
Rockford, IL, USA) and Kodak X-ray film.
Densitometric analysis was performed using the
Image J 5 Program. Equal loading was controlled
by Ponceau staining.
– α1-AT bioactivity measured by the Elastase Inhibitory
Capacity (EIC) colorimetric assay: The inhibition that
plasma and BALF samples exerted on the in vitro
elastase-induced N-succinyl-Ala-Ala-Ala-p-nitroanilide
(SLAPN; Sigma) hydrolysis test was studied [25, 26].
The rate of p-nitroanilide released at 25 °C was
followed for 3.5 min at 405 nm wavelength using a
microplate spectrophotometer reader (BIO-TEK®
Instruments, Inc. Winooski, Vermont, USA). Serial
dilutions were assayed in order to calculate the
volume of plasma and BALF needed to produce
50 % inhibition of the in vitro elastase activity.
Results were expressed as 1/dilution required for
50 % inhibition.
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c) α2-macroglobulin: Plasma and BALF levels were
measured by ELISA (Abcam Inc. Cambridge, MA,
USA) according to the manufacturer’s instructions.
Microplates were read using a microplate reader
(BIO-TEK® Instruments, INC. Winooski, Vermont, USA).
mRNA expression of α1-AT and α2-MG in liver samples
a) RNA extraction and reverse transcription: Total
RNA was isolated from snap frozen liver samples using
Total RNA Mini Kit Tissue (Geneaid Biotech Ltd.,
Taiwan) according to the manufacturer’s instructions
and 2 μg of total RNA of each sample was treated with
DNAse I (Amplification grade; Invitrogen, USA). The
single-strand cDNA was synthesized using Superscript
II Reverse transcriptase (Invitrogen, USA) in 20 μl total
volume with Random Primer (Invitrogen, USA) according
to manufacturer’s instructions.
b) Semiquantitative Real-Time RT-PCR: The 7500 Fast
Real-Time PCR System (Applied Biosystems) was used
to quantify the relative gene expression of α1-AT and
α2-MG in rat liver; GAPDH was chosen as the
housekeeping gene. PCR was performed using
sequence-specific primers for α1-AT, α2-MG and
GAPDH (Table 1) in a reaction mix containing Fast
SYBR Green PCR Master Mix (Invitrogen, USA). All
real-time PCR assays were performed in duplicate.
The thermal cycling conditions included an initial acti-
vation step at 95 °C for 20 s, followed by 40 cycles at
95 °C for 3 s and 60 °C for 30 s with an ultimate melting
cycle (95–60 °C). The annealing condition for GAPDH
was 66 °C for 30 s. In order to verify the specificity of
each product, amplified products were subjected to
melting curve analysis as well as to electrophoresis.
Relative real-time RT-PCR quantitation was performed
according to Livak and Schmittgen [27], using the com-
parative threshold cycle (CT) values [28]. The Delta-








where, (CT,Target - CT,GAPDH) time 0 represents normalized
expression in controls, and (CT,Target - CT,GAPDH)time X is
the normalized expression at the different time points of
the study. The relative fold expression (RFE) of the tar-
get genes was calculated as in Eq. 2:
RFE ¼ 2‐ΔΔCT ð2Þ
Statistical analysis
Non parametric analysis of variance (Kruskall-Wallis)
and linear regression analysis were used [29]. Graph Pad
Prism 5.0 software was utilized. A p value < 0.05 was
considered statistically significant.
Results
Gastric fluid-induced acute lung injury and pro-
inflammatory mediators
Histologic evaluation of the lung was performed at all-
time points after instillation according to ATS recom-
mendations [21]. Figure 1 shows results at several time
points after instillation. At 4 h, increased alveolar thick-
ening by interstitial edema and inflammatory cell infil-
tration, along with abundant protein-rich intra-alveolar
exudate containing neutrophils and red blood cells were
seen, adopting a peribronchiolar distribution. These
changes became more intense at 12 and 24 h, with
patchy consolidation due to coalescence of affected
areas. At 4 and 7 days, foreign-body giant cells, either
isolated or forming granulomas were frequently ob-
served, along with intra-alveolar buds of granulation tis-
sue. In the first 4 to 24 h, there was a large increase in
inflammatory cells (more than 80 % PMNn cell predom-
inance) whereas at days 4 and 7, mononuclear cells pre-
dominated [5].
Markers of increased alveolar-capillary barrier perme-
ability at different times after whole gastric fluid instilla-
tion are shown in Fig. 2 and Table 2. Using several
markers of alveolar-capillary barrier permeability, the
largest increase in permeability was seen at 4 h. Figure 2
shows that at 4 h there was a large extravasation of the
intravenous Evans blue dye into BALF with gradual re-
turn to control values at 12–24 h, suggesting progressive
restitution of barrier integrity. Non-significant changes
in blood levels of Evans blue dye after IV injection were
found. As seen in Table 2, lung wet-to-dry weight ratio
showed a large but transient increase at 4 h (p < 0.001)
with return to control values at 12 h. Table 2 also shows
that BALF total protein concentration increased mark-
edly (76 times the control value, p < 0.001) at 4 h and,
Table 1 Primer sequences for RT-PCR and product sizes
Gene name Primer sequence Product
size
α1-AT sense: 5′- cca cgg tga agg tgc cca tga tga-3′ 375 bp
antisense: 5′- tca gca cag cct tat gca cag cct-3′
α2-MG sense:5′-atc tac atg gtg atg gtt cc-3′ 209 bp
antisense:5′- acc tca ttg gat gaa gac tg-3′
GAPDH sense: 5′-acc aca gtc cat gcc atc ac -3′ 451 bp
antisense: 5′-tcc acc acc ctg ttg ctg ta -3’
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although at a significantly lower level, it remained ele-
vated at 12 and 24 h (p < 0.001).
Changes in cytokines in BALF and lung tissue homog-
enates at different times after instillation are illustrated
in Fig. 3. Pro-inflammatory cytokines IL-6, IL-1β and
TNF-α were non-detected in control BALF and all
showed an early increase in concentration after instilla-
tion, being mild for TNF-α and very large for IL-6
(Fig. 3a) and IL-1β (Fig. 3b). Whereas IL-6 increased
mainly in BALF, IL-1β increased mainly in lung tissue
homogenate, likely indicating differences in the cellular
source of these cytokines. The highest levels of IL-6
were seen at 4 h (8,400 pg/ml, p < 0.001) with a progres-
sive reduction later on. The highest levels of IL-1β were
seen at 12 h (10,900 pg/ml, p < 0.001) with a significant
reduction at 24 h (p < 0.01). Levels of TNF-α both in
BALF and lung tissue homogenate showed a brief and
moderate increase at 4 h (600 pg/ml, p < 0.001), with sig-
nificant reduction thereafter (Fig. 3c). On the other
hand, IL-10 levels showed a progressive increase be-
tween 4 and 24 h (p < 0.001) but only in BALF. In lung
Fig. 1 Lung inflammatory reaction after instillation of whole gastric fluid. Light microscopy (hematoxylin-eosin) of rat lung at 4, 12, and 24 h and,
at days 4 and 7 after gastric fluid instillation. Intra-alveolar inflammatory and red blood cells along with proteinaceous material are seen at 4 h,
with a peribronchiolar distribution. At 12 and 24 h, the inflammatory infiltrate is more intense with coalescence of affected areas and patchy
consolidation. At days 4 and 7, intra-alveolar buds of granulation tissue (arrows) along with foreign-body giant cells, either isolated or forming
granulomas are seen. Original magnification: 100×. C: control; d: days; h: hours
Fig. 2 Evans blue dye extravasation into BALF after instillation of
gastric fluid. A large extravasation of dye is seen at 4 h, with gradual
return to control values thereafter. Values are means ± SD for n = 5
for each time point. ***: p < 0.001 with respect to control values. C:
controls; h: hours
Table 2 Markers of alveolar - capillary barrier derangement
Control 4 h 12 h 24 h 4 d
Wet-to-dry weight ratio
Mean 4,60 5,67 *** 4,71 4,56 4,80
S.D. 0,10 1,01 0,21 0,11 0,24
BALF total protein content
Mean (mg x mL−1) 0,19 14,52 *** 10,78 *** 9,51 *** 0,88
S.D. 0,1 7,1 5,46 4,04 0,39
h hours, d days
***: p < 0,001 with respect to control values
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tissue homogenates, IL-10 remained detectable but un-
changed throughout (Fig. 3d).
Changes in all measured cytokines in both BALF and
lung tissue were transient and all the cytokines studied
reached control levels at day 4.
In spite of the high levels of pro-inflammatory cytokines
produced in the lung after instillation of gastric fluid, only
IL-6 was detected transiently in plasma at 4 h (Fig. 3e).
Acute phase proteins in blood
Changes in the levels of acute phase proteins in blood
are shown in Figs. 4 and 5.
Fibrinogen concentration in plasma was not increased
at 4 h but showed a mean increase of 68 % at 12 and 24 h
(p < 0.001), with return to control values at day 4 (Fig. 4a).
α2-MG concentration in plasma was not increased at
4 h but showed a mean increase of 7.5 times above
Fig. 3 Pro-inflammatory cytokines and IL-10 levels in BALF, lung tissue homogenate and blood after instillation. a In the lung, IL-6 levels increased
mainly in BALF, with a peak at 4 h and a progressive reduction to become non detectable at 4d. b IL-1β levels increased mainly in lung tissue
homogenate with a peak level at 12 h and a significant reduction thereafter. c Levels of TNF-α showed a brief and moderate increment at 4 h
both in BALF and lung tissue homogenate, with a significant reduction thereafter. d IL-10 levels in BALF showed a progressive increase between
4 h and 24 h and became non detectable at 4d, without changes in lung tissue homogenate. e In spite of the high levels of pro-inflammatory
cytokines observed in the lung, only IL-6 was detected in plasma at 4 h after instillation. Open bars correspond to cytokine levels in BALF, solid
bars correspond to cytokine levels in lung tissue homogenate and the hatched bar corresponds to IL-6 levels in plasma. Results are means ± SEM.
*: p < 0.05; **: p < 0.01; ***: p < 0.001 with respect to control values. C: controls; h: hours; d: days; N.D.: non detectable
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control values at 12 h (p < 0.01) and of 13.4 times at
24 h (p < 0.001), with significant reduction thereafter, to
reach control values at day 7 (Fig. 4b).
α1-AT abundance and bioactivity in plasma after
instillation of whole gastric fluid are shown in Fig. 5. Fig-
ure 5a illustrates changes in plasma α1-AT abundance in
a representative Western blot. The ~55 kDa α1-AT im-
munoreactive band that is seen in the control sample in-
creases at 24 h after treatment and decreases at day 4.
Figure 5b shows the results of the densitometric analysis
of α1-AT Western blots, normalized by their corre-
sponding Ponceaus and expressed as times over control
values (n = 4 for each time point). α1-AT immunoreac-
tivity increased 1.5 times at 24 h after instillation (p <
0.01) and was back to control values at day 4. Figure 5c
shows that changes in plasma α1-AT bioactivity were
similar to changes in immunoreactivity. At 24 h, α1-AT
bioactivity increased significantly (1.3 times the control
values (p < 0.01)), with return to control values at day 4.
The time course of changes in blood concentration of
these three acute phase proteins, preceded by elevation
of IL-6 levels in blood, was compatible with a rodent
acute phase response profile [17].
Gene expression of antiproteases α1-AT and α2-MG in the
liver
In Fig. 6a, the two- to three-fold mean increase in α1-
AT mRNA, that was seen at 4 h and persisted during
the first 24 h, did not reach statistical significance.
Nevertheless, this change in expression preceded small
but significant changes in α1-AT protein abundance and
bioactivity in blood with a liver acute phase response
profile.
Figure 6b shows that changes in α2-MG mRNA ex-
pression were significantly larger than for α1-AT mRNA
expression, with a forty-fold mean increase at 4 h, a 400-
fold mean increase at 12 h (p < 0.01) and a 900-fold
mean increase at 24 h (p < 0.05) and return to control
values at day 4. Changes in hepatic α2-MG mRNA ex-
pression preceded changes in blood α2-MG protein
concentration.
Changes in lung antiprotease protection after instillation
of gastric fluid
Figure 7 illustrates lung consequences of local and hep-
atic changes induced by instillation of whole gastric fluid
on lung antiproteases α1-AT and α2-MG.
BALF α1-AT abundance by Western blot analysis
Figure 7a shows a representative α1-AT Western blot of
BALF samples. Control BALF shows two α1-AT immuno-
reactive bands in the ~55–60 kDa molecular size range,
corresponding to the native α1-AT described in rodents
[30]. After instillation, immunoreactivity of these bands
increases and new bands are seen in the first 4–24 h: a
~88 kDa band corresponding to the [elastase-α1-AT]
complex [31] and a ~45–50 kDa band corresponding to
the α1-AT proteolytic fragment, derived from the inter-
action between elastase and α1-AT [31, 32]. At day 4, the
immunoreactivity pattern of BALF α1-AT is similar to
that in the control. Figure 7b shows the densitometric
analysis of Western blots for α1-AT (n = 5 for each time
point), with a mean 4.2 fold increase in α1-AT immunore-
activity that is evident at 4 h and remains elevated up to
24 h after instillation (p < 0.001).
BALF α1-AT bioactivity
Figure 7c shows changes in BALF α1-AT bioactivity
after instillation. A significant increase in bioactivity
was seen at 4 h (p < 0.001) with further increase later
Fig. 4 Changes in plasma fibrinogen and α2-MG concentration after
instillation of whole gastric fluid. a Plasma levels of fibrinogen were
not significantly different than in controls at 4 h. They increased at
12 h-24 h and returned to control values at 4d. b Plasma levels of
α2-MG remained stable at 4 h, increased at 12 h, further increased
reaching a peak at 24 h and decreased later on, but with still significantly
high levels at 4d. Results are means ± 1SD; **: p< 0.01; ***: p < 0.001 with
respect to control values; †: p < 0.05 with respect to the precedent time
point value. C: controls; h: hours; d: days
Ayala et al. Respiratory Research  (2016) 17:71 Page 7 of 15
on. At 24 h α1-AT bioactivity was significantly higher
than at 4 h (p < 0.001) and returned to control level
at day 4.
BALF α2-MG concentration
Figure 7d shows changes in α2-MG concentration. This
high molecular weight protein was found in very low
concentration in control BALF. A progressive increase
in concentration was seen in the first 24 h (p < 0.001),
starting at 4 h. A mean 51-fold increase in concentration
at 4 h (that did not reach statistical significance), 105-
fold increase at 12 h and 194-fold increase at 24 h is
shown, with return to control levels at day 4, despite still
increased levels of α2-MG in plasma.
Two-phase response in antiprotease enrichment of the
alveolar spaces
As seen in Fig. 7, α1-AT bioactivity (7c) and α2-MG
concentration (7d) in BALF at 4 h exhibit a similar large
increment: a 40-fold and a 51-fold increase respectively
in comparison to control values. These early changes in
BALF occur without changes in blood levels of antipro-
teases as seen in Figs. 4b and 5. Instead, they occur in
relation to the alveolar-capillary barrier derangement ob-
served at 4 h, as illustrated by Evans blue dye extravasa-
tion and the significant increase in BALF total protein
content and in lung tissue wet to dry weight ratio.
After the first 4 h, there is a further rise in the levels
of both antiproteases in BALF, but with different slopes,
as seen in Fig. 8. This figure summarizes the magnitude
of changes in BALF antiproteases occurring in relation
to their increased blood levels (as percent changes from
values at 4 h). An extra 18 % increase in α1-AT bioactiv-
ity (Fig. 8a) and an extra 281 % increase in α2-MG con-
centration (Fig. 8b) were found in BALF. These BALF
changes occur together with an increment in the levels
of both antiproteases in blood (Figs. 4 and 5). During
this period of time, there is no further derangement of
the alveolar-capillary membrane. In fact, Evans blue dye
extravasation returns to control values (Fig. 2), BALF
total protein content decreases progressively up to 40 %
Fig. 5 Changes in plasma α1-AT abundance and bioactivity after
instillation of whole gastric fluid. a Representative Western blot of
plasma samples illustrating the time course of changes in plasma
α1-AT abundance. The ~55 kDa α1-AT immunoreactive band seen
in the control sample shows a significant enlargement at 24 h.
b Densitometric analysis of Western blots, normalized by their
corresponding Ponceaus and expressed as times over control values
(n = 5 for each time point). α1-AT immunoreactivity increased 1.5
times the control values at 24 h and was back to control levels at
4d. c Plasma α1-AT bioactivity increased 1.3 times with respect to
control values at 24 h with return to control values at 4d. Bars are
means ± 1SD; **: p < 0.01 with respect to control values. C: controls;
h: hours; d: days
Ayala et al. Respiratory Research  (2016) 17:71 Page 8 of 15
and wet to dry weight ratio reaches control values at
12 h (Table 2). Thus, during this period in which there
is no further increase in permeability, antiprotease en-
richment of the alveolar spaces likely occur in relation to
the increment in the antiprotease capillary-alveolar con-
centration gradient, due to increased blood levels of
antiproteases.
Figure 9 shows the effects of the two processes that
occur in the first hours after instillation and that deter-
mine largely increased levels of α2-MG in BALF: a) the
alveolar-capillary barrier derangement and b) the in-
crease in blood concentration of α2-MG. In Fig. 9a, α2-
MG levels in BALF at 4 h do not correlate with α2-MG
levels in blood, indicating that BALF levels of α2-MG
are determined by derangement of the alveolar-capillary
barrier that loses its protein size selectivity. In Fig. 9b, a
significant positive correlation is seen between α2-MG
levels in blood and α2-MG levels in BALF at 12–24 h.
Data on plasma and BALF α2-MG concentration fit a
lineal regression of the form y = 0.0095x + 1.941 (r =
0.64; p = 0.028). In this time period, markers of increased
alveolar capillary barrier permeability progressively de-
crease, indicating that BALF levels of α2-MG are
determined by the APR that increases the α2-MG con-
centration gradient. In Fig. 9c, still elevated levels of α2-
MG in blood at day 4 do not result in elevated levels of
α2-MG in BALF, reflecting restoration of the normal
protein size selectivity of the alveolar-capillary barrier.
Figure 9c also shows that at day 7, blood and BALF
levels of α2-MG are back to control values.
Discussion
Our results show for the first time, that a severe lung in-
flammatory reaction induced by orotracheal instillation
of whole gastric fluid elicits a liver acute phase response,
with elevation of acute phase proteins in the blood
stream. The main lung antiproteases are part of this re-
sponse, since mRNA transcription of α1-AT and mainly
of α2-MG, is induced early in the liver, preceding eleva-
tion of the acute phase proteins in blood. Our results
also show that the liver response contributes to the
enrichment of the alveolar spaces with acute phase
proteins that are important lung antiproteases. We iden-
tified a two-phase response in antiprotease enrichment
of the alveolar spaces after aspiration, related to an early
increase in alveolar-capillary barrier permeability and a
later increment in capillary-alveolar antiprotease con-
centration gradient, due to increased blood concentra-
tion of antiproteases by increased liver synthesis.
Biology of the acute phase response
The systemic inflammatory response is a collection of
coordinated physiologic changes initiated during early
stages of inflammation as part of the early innate
defense, triggered by a variety of stimuli with the goal of
achieving homeostasis. A prominent feature of this re-
sponse is synthesis of several proteins mainly by the
liver, under the control of cytokines originating at the
site of injury [16], referred to as the liver acute phase re-
sponse (APR). Changes in blood during the hepatic APR
have been studied in rodents in response to stimuli not
affecting the lung primarily, such as LPS and turpentine
administration and exposition to thermal injury, and a
number of APPs have been shown to participate. With
these stimuli, the rodent APR starts a few hours after
the insult, reaches a peak 24–48 h later and is back to
baseline values at day 7 [17, 18, 33]. In general, it is as-
sumed that elevation of APPs in blood have beneficial
effects based largely on the known function of each of
the individual proteins involved and on logical specula-
tions as to how these might be useful in inflammation
Fig. 6 Changes in liver α1-AT and α2-MG gene expression after
instillation of whole gastric fluid. a α1-AT gene expression: a non-sig-
nificant two- to three-fold increase in liver α1-AT mRNA expression was
seen between 4 h and 24 h. b α2-MG gene expression: a mean forty-
fold increase at 4 h, 400-fold increase at 12 h and 900-fold increase at
24 h in α2-MG mRNA expression was seen. Results are means ± SEM; *:
p < 0.05; **: p < 0.01 with respect to control values. C: controls; h: hours;
d: days
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Fig. 7 Changes in α1-AT and α2-MG in BALF after instillation of whole gastric fluid. a Representative Western blot illustrating changes in BALF
α1-AT immunoreactivity. Two bands in the 55–60 kDa, corresponding to the native antiprotease are seen. After instillation, an approximately
88-kDa band corresponding to the [α1-AT-elastase] complex and a 45–50 kDa band, corresponding to the proteolytic fragment derived from the
interaction between α1-AT and elastase are present at 4 h, 12 h and 24 h. In addition, the immunoreactivity of the 55–60 kDa band increases
markedly at these time-points. Ponceau staining was used as a loading control. b Densitometric analysis of five independent Western blots. Total
α1-AT immunoreactivity increased 4.2 times over control values at 4 h, remained elevated up to 24 h and returned to control values at 4d. Proteolytic
band immunoreactivity was present only between 4 h and 24 h. Open bars correspond to the means ± 1SD of densitometric arbitrary units of total
α1-AT immunoreactivity. Hatched bars correspond to immunoreactivity of the α1-AT proteolytic band. c Changes in α1-AT bioactivity in BALF. Elastase
inhibitory capacity increased 49 times over control values at 4 h, with a further increase to 58 times the control values at 24 h and returned to control
levels at day 4. d Changes in α2-MG concentration in BALF. α2-MG concentration increased significantly at 12 h, with a peak at 24 h. At 4d, α2-MG
concentration was back to control values. Results are means ± 1SD; *: p < 0.05; ***: p < 0.001 with respect to control values; ††: p < 0.01; †††: p < 0.001
with respect to 4 h. C: controls; h: hours; d: days
Fig. 8 BALF antiprotease enrichment after the first 4 h, due to increased capillary-alveolar concentration gradient without further increase in
permeability. a Changes in BALF α1-AT bioactivity and BALF total protein content between 4 h and 24 h after instillation. At 24 h, while total
protein content falls 40 %, BALF α1-AT bioactivity increases 18 % above values observed at 4 h. b Changes in BALF α2-MG concentration and
BALF total protein content between 4 h and 24 h after instillation. At 24 h, while total protein content falls 40 %, BALF α2-MG concentration
increases 281 % above values observed at 4 h. h: hours
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[16]. However, in the last few years, some negative impli-
cations of the hepatic APR have also been proposed,
since the increase in blood of proteins with pro-
coagulant effects such as fibrinogen, in relation to lung
inflammation induced by urban air pollution and
cigarette smoking, has been implicated in adverse car-
diovascular effects [34]. In addition, this response has
been implicated in the progression of lung damage in
patients with COPD [35]. Unfortunately, studies relating
cardiovascular morbidity and mortality during episodes
of increased air pollution have focused only on C-
reactive protein and APPs with pro-coagulant effects
and have not evaluated the full spectrum of proteins that
are known to be co-expressed, among them several anti-
proteases that can reach the lung improving its defense
properties.
Acute phase response elicited by gastric fluid-induced
lung inflammation
Although the innate immune response to gastric con-
tents aspiration has been extensively studied in the local
lung environment, we have very little insights into extra-
pulmonary effects elicited by aspiration that could have
implications modifying lung inflammation and the prog-
nosis of a single aspiration event. As a matter of fact,
there is little information on the cascade of cytokines re-
leased in the lung during aspiration-induced ALI that
could induce an APR [2, 5]. It has been proposed that
the pattern of APPs produced in response to an injury
and the cytokines involved in their regulation depends
on the nature of the inflammatory stimulus [36]. Al-
though it is known that IL-6, IL-1β and TNF-α modulate
the synthesis of APPs in adult human hepatocytes, IL-6
is the major cytokine involved in the synthesis of the full
spectrum of APPs [16, 33, 37]. IL-6 responsive regula-
tory elements have been found in the α1-AT gene that
are responsible for both basal and induced expression of
α1-AT in different human cell types and in rat hepato-
cytes [33, 38, 39]. On the other hand, it has been shown
that IL-6 defective mice have a severely compromised
APR to turpentine-induced tissue damage, as well as an
impaired response following LPS injection [40, 41] and
bacterial pneumonia [19]. In our model, IL-6 may play a
role in the APR, since it was the only pro-inflammatory
cytokine found to have increased levels in blood preced-
ing changes in APPs, despite very high levels of other
pro-inflammatory cytokines in the lung. It is also pos-
sible however, that other regulators could be involved in
our model, since for instance in rats, CINC-1 the coun-
terpart of human IL-8, has also been involved in APP
production [42]. In our study, the high levels of IL-6 and
TNF-α observed in BALF in comparison with lung tissue
homogenate suggest that epithelial and alveolar mono-
nuclear resident cells might be the source of these cyto-
kines. In this regard, Fujii et al. have shown that the
interaction between macrophages and epithelial cells has
a synergistic effect on the production and release of me-
diators involved in the systemic inflammatory response
[43]. With regard to the cytokine IL-10, we found that
its concentration in BALF increases at the time pro-
inflammatory cytokine levels decrease, in agreement
with the known role of IL-10 limiting the cascade of pro
inflammatory cytokines in lung inflammation [44].
In the literature, there is no information on the type
and kinetics of APP production during gastric juice-
induced ALI. We found a significant increase in the
three APPs studied, with a time course of a rodent APR
[17, 18, 33]. Additionally, the increment in α1-AT
Fig. 9 Relationship between plasma and BALF α2-MG concentrations.a Relationship between plasma and BALF α2-MG concentration at 4 h. Lack
of correlation (r = 0.44; p N.S.) between plasma and BALF levels of α2-MG is seen. Increased BALF α2-MG concentration without an increase in
plasma α2-MG concentration indicates loss of the protein size selectivity of the alveolar-capillary barrier. b Relationship between plasma and BALF
α2-MG concentration at 12–24 h. A significant positive correlation (r = 0.647; p = 0.0028) between plasma and BALF levels of α2-MG at 12–24 h is
seen, indicating that BALF levels of α2-MG during this period are determined by the increase in α2-MG capillary-alveolar concentration gradient,
due to the liver acute phase response. c Relationship between plasma and BALF α2-MG concentration at 4 and 7d. Still elevated levels of α2-MG
in blood at 4d (solid circles) do not result in elevated levels of α2-MG in BALF, reflecting restoration of the normal protein size selectivity of the
alveolar-capillary barrier. At 7d (open circles), blood and BALF levels of α2-MG are back to control values. h: hours; d: days
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concentration in blood was associated with a propor-
tional increase in its activity. The increment in blood
levels of α1-AT and α2-MG was preceded by an increase
in their mRNA expression in the liver, with the largest
increase being that of α2-MG, which is considered to be
the main acute phase antiprotease in the rat [17]. As a
matter of fact, α1-AT, α2-MG and fibrinogen belong to
the same group of APPs [16], responding to the same
type of signal, involving activation of intracellular tyro-
sine kinase JAK and the acute-phase responsive factor,
now called STAT3 [36, 45, 54].
On the basis of timing and magnitude of the changes
observed in our model, we speculate that the increase in
liver synthesis of fibrinogen, α1-AT and α2-MG could be
mediated by the IL-6 signaling, that is known to partici-
pate in activation of the JAK/STAT3 cascade. Future stud-
ies using IL-6 inhibition are warranted to further evaluate
the role of this cytokine in gastric juice-induced APR.
Although α1-AT is the main lung antiprotease in
steady-state conditions, exhibiting a broad range of anti-
inflammatory and immunoregulatory activities [37, 46],
it is not the main acute phase antiprotease in the rat. It
is produced primarily by the liver, with additional
sources such as peripheral blood monocytes and alveolar
macrophages contributing with a small fraction to total
synthesis. Literature shows that similar to the liver, these
additional sources are also known to respond to inflam-
matory stimuli with a small local APR, but their contribu-
tion to the increment in capillary-alveolar concentration
gradient and to BALF APP levels is small [19, 47].
It has been shown that α1-AT is produced as part of
the liver APR after turpentine injection in guinea pigs
[48] and rats [17]. Support for a beneficial effect of α1-
AT as part of the APR is provided by a study in a rat
model of renal ischemia-reperfusion injury, in which the
administration of α1-AT, at a dose that results in plasma
levels similar to those observed during an APR, reduces
inflammation, apoptotic activity and tissue damage [49].
Interestingly, we found complex formation between α1-
AT and elastase in BALF between 4 and 24 h after instil-
lation, providing evidence of the functionality of this
antiprotease in our model.
With regard to α2-MG, it inhibits different types of
proteases and is also a carrier and regulator of the func-
tion of several cytokines. Its large size prevents it from
diffusing easily through the normal alveolar-capillary
barrier and thus, it is found in very low concentration in
normal alveolar spaces [46, 50]. It reaches the alveolar
spaces in significant amounts whenever there is alveolar-
capillary barrier derangement. Its role as a marker of
alveolar-capillary barrier permeability has been studied
in human acute respiratory distress syndrome [47]. In
this condition, α2-MG has been found forming com-
plexes with proteases and IL-8 [51]. Very little is known
about its role as an acute phase protein in humans, how-
ever, it is recognized as the main acute phase antipro-
tease in the rat [17].
Impact of the hepatic APR on lung antiprotease defense
Containing the lung inflammatory response induced by
gastric juice is critically important in order to inhibit
progression to a persistent systemic inflammatory re-
sponse fueled by persistently increased cytokine produc-
tion. In this regard, liver-newly synthetized antiproteases
reaching the alveolar spaces may play an important role
limiting lung inflammation. It has recently been shown
that the APR has a role improving animal survival in
experimental bacterial pneumonia [19, 52, 53] and
although in these studies antiproteases were not evalu-
ated, other APPs that were increased in blood were
found increased in BALF [19]. On the other hand, re-
search using APR-null mice in pneumonia has shown
that in the absence of an APR, APPs do not increase in
BALF and there is increased animal mortality [19, 54,
55]. Our results showed a highly significant enrichment
in antiprotease content of the alveolar spaces, with a
mean 58-fold increase in α1-AT activity and a mean
192-fold increase in α2-MG concentration in BALF.
Given the fact that in our model, the acidic component
of gastric contents triggers an early derangement of the
alveolar-capillary barrier that precedes in several hours
the increment in blood APP concentrations, we were
able to show a two-phase response in the enrichment of
the alveolar spaces with antiproteases.
Two-phase response in the enrichment of the alveolar
spaces with antiproteases
The first phase is characterized by an early and large in-
crement in BALF antiprotease concentration and occurs
prior to APP elevation in blood, thus not due to the
APR, and instead due to derangement of the alveolar -
capillary barrier that loses its protein size selectivity, fa-
cilitating the passage of both small (α1-AT) and large
(α2-MG) molecular weight proteins to the alveolar
spaces [50]. This phase contributes with a 40-fold in-
crease in lung α1-AT bioactivity and a 51-fold increase
in α2-MG concentration.
The second phase is contributed by the liver acute
phase response that increases the capillary-alveolar
concentration gradient for α1-AT and mainly for α2-
MG. This phase provides an extra 18 % increase in
BALF α1-AT bioactivity and an extra 281 % elevation
in BALF α2-MG concentration (above the high levels
provided by the first phase of antiprotease enrichment
found at 4 h), in the context of significant reduction in
total protein content in the same period of time. Inter-
estingly, the antiprotease with the largest change in
BALF in this phase is α2-MG that has also the largest
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change in blood concentration and in liver mRNA
expression.
This two-phase response in lung antiprotease enrich-
ment is likely to be unique to this model and not easy to
detect in other models of ALI, in which alveolar-
capillary barrier derangement is delayed by depending
more on the effects of the inflammatory response than
on the direct early effect of the acidic component of gas-
tric juice.
It is also possible that a small part of the lung en-
richment in antiproteases may come from alveolar
mononuclear cells, that are known to respond to in-
flammatory stimuli with a low grade local lung APR
[19, 47]. However, given the time-course of changes,
this factor is unlikely to play a major role in our model,
since antiprotease flooding occurs very early, prior to
and during PMNn cell infiltration, and prior to mono-
nuclear cell predominance, which occurs after day 4 [4,
5]. Furthermore it is accepted that the small amount of
α1-AT released from monocytes serves more as a mi-
croenvironmental front line defense against proteases
provided by the same monocytes [47].
On the basis of our results, local lung effects of gastric
fluid damaging the alveolar-capillary barrier act in con-
cert with lung inflammation-induced hepatic acute phase
response to favour the arrival of new antiproteases to
improve lung defense. Evidence of complex formation
between α1-AT and elastase released from the inflamma-
tory cells in the first 24 h provide support for the idea
that antiprotease enrichment of the alveolar spaces plays
a role limiting lung injury by proteases in this model.
Protease inhibition may represent one of many mecha-
nisms involved in the significant capacity of the lung to
repair the severe ALI induced by gastric fluid recently
reported by our group [5].
We postulate that antiprotease supplementation dur-
ing the window of opportunity in which the hepatic APR
co-exists with increased permeability, could be useful
during ALI, in species without an increment in α1-AT
and/or α2-MG in the liver acute phase response. In
addition, it could be possible that either liver diseases or
polymorphisms in the acute phase response genes may
constitute susceptibility factors for lung or other tissue
injuries. In this regard, increased lethality from lung
damage has been shown by Borzio et al. [56] in patients
with liver cirrhosis. On the other hand, a reduced APR
was implicated in the increased lethality observed in ex-
perimental cirrhosis [57]. In the light of our results it is
possible that antiproteases as part of APR could be in-
volved in the results of the above mentioned studies.
In addition, since the APPs in blood remain elevated
for several days, it is likely that they may impact lung re-
sponse to repetitive events of aspiration. Future studies
of this response with different lung inflammatory stimuli
should consider the evaluation of the full range of pro-
teins that are co-expressed, including the antiproteases,
in order to have a better appreciation of the net effects
of the liver APR in lung defense.
Conclusions
Our results provide insights into the role of the liver in
the pathogenesis of acute lung injury. A severe lung in-
flammatory reaction induced by gastric fluid elicits a
liver acute phase response involving the main lung anti-
proteases. Liver changes act in concert with the derange-
ment of the alveolar-capillary barrier to enrich the
alveolar spaces with antiproteases. These results support
the possibility of therapeutic interventions such as anti-
protease supplementation during the window of oppor-
tunity in which the hepatic APR co-exists with increased
permeability.
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